TGFB1 and cancer: Few inhibitors that address the unmet clinical necessities in cancer immunotherapies targeting TGF-β/SMAD signaling pathway are galunisertib (LY2157299) (156), vactosertib (TEW-7197) (157), LY2109761 (158), LY3200882 (159), MDV6058 (PF-0695229), GFH018 (160), YL-13027 (157), AGMB-129 (ORG-129) (161), SH3051, Trabedersen (AP 12009) (157), fresolimumab (GC1008) (162), AVID200 (163), ABBV-151 (164), SRK-181 (165), and bintrafusp alfa (M7824) (166).